Come back later: ODAC rejects accelerated approval of neoadjuvant Keytruda in TNBC

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

In a unanimous vote, the FDA Oncologic Drugs Advisory Committee recommended against an accelerated approval for Keytruda for patients with high-risk, early-stage triple-negative breast cancer, in combination with chemotherapy as neoadjuvant treatment, then as a single agent as adjuvant treatment after surgery.

The company was seeking approval based on the surrogate endpoint of pathologic complete response.

The advisory committee’s recommendation—reached in a 10:0 vote with no abstentions at the Feb. 9 meeting—was to defer any approval decision until more mature data from the company’s ongoing clinical trial are available.

In an odd regulatory/linguistic twist, a Yes vote indicating “Yes, defer,” amounted to a “No, do not approve.”

“In the couple of years that I’ve been on the ODAC, this is the first time that I’ve encountered a voting question that basically said, should we defer this, as opposed to the Yes or No. Has the efficacy and safety been demonstrated, so Yes or No, we should approve,” ODAC Chair Philip C. Hoffman, professor of medicine at the University of Chicago Section of Hematology/Oncology Department of Medicine, said after the votes were cast.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Paul Goldberg
Editor & Publisher
Table of Contents

YOU MAY BE INTERESTED IN

Multiple components of the healthcare and public health systems are currently under scrutiny. One of them is reportedly the U.S. Preventive Services Task Force (USPSTF: “Task Force”), established in 1984 and managed by the Agency for Healthcare Research and Quality.  It was created to maintain an ongoing evaluation of disease prevention and screening interventions that...

Paul Goldberg
Editor & Publisher

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login